Technical Analysis for IONS - Ionis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 67.4 -0.56% -0.38
IONS closed down 0.56 percent on Friday, May 17, 2019, on 73 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Down
See historical IONS trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup -0.56%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.56%
Calm After Storm Range Contraction -0.56%
Calm After Storm Range Contraction 1.28%
Outside Day Range Expansion 1.28%
Calm After Storm Range Contraction 0.99%
NR7 Range Contraction 0.99%
Inside Day Range Contraction 0.99%

Older signals for IONS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, focuses on developing drugs for patients with severe and rare diseases. It markets KYNAMRO for the treatment of homozygous familial hypercholesterolemia. The company's drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; IONIS-TTRRx, a drug for the treatment of patients with various forms of TTR amyloidosis, including familial amyloid polyneuropathy, familial amyloid cardiomyopathy, and wild-type TTR amyloidosis; and nusinersen, a drug for the treatment of infants and children with spinal muscular atrophy. It is also developing Custirsen, which is in two Phase III studies to treat cancer; and Plazomicin that is Phase III study for the treatment of severe bacterial infection. In addition, the company is developing products, which are Phase II clinical trials include IONIS-DMPK-2.5Rx for myotonic dystrophy type 1; IONIS-HTTR for huntington's disease; ATL1103 for acromegaly; IONIS-FXIRx (BAY 2306001) for clotting disorders; IONIS-APO(a)-LRx for high Lp; IONIS-ANGPTL3-LRx for mixed dyslipidemias; Apatorsen (OGX-427) and IONIS-STAT3-2.5Rx (AZD9150) for cancers; EXC 001 (PF-06473871) for scarring; ATL1102 for multiple sclerosis; and RG-101 for hepatitis C virus infection, as well as products for the treatment of diabetes and obesity. Further, its products in Phase I clinical include IONIS-GCCRRx for cushing's syndrome; IONIS-PKKRx for hereditary angioedema; RG-012 for alport syndrome; IONIS-AR-2.5Rx (AZD5312) for prostate cancer; IONIS-HBVRx for hepatitis B virus infection; IONIS-GSK4-LRx for ocular disease; and IONIS-DGAT2Rx for nonalcoholic steatohepatitis. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
Cancer Organ Systems Diabetes Cancers Drug Discovery Prostate Cancer Disorders Obesity Genetics Multiple Sclerosis Neurological Disorders Spinal Muscular Atrophy Treatment Of Diabetes Huntington's Disease Orphan Drugs Acromegaly Cushing's Syndrome Hepatitis C Virus Infection Hereditary Angioedema Therapeutic Gene Modulation Antisense RNA Severe And Rare Diseases Familial Amyloid Polyneuropathy Familial Chylomicronemia Syndrome Familial Partial Lipodystrophy Homozygous Familial Hypercholesterolemia
Is IONS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 86.58
52 Week Low 40.91
Average Volume 1,327,399
200-Day Moving Average 58.6844
50-Day Moving Average 76.3486
20-Day Moving Average 70.907
10-Day Moving Average 68.067
Average True Range 2.8378
ADX 45.96
+DI 8.4232
-DI 26.3939
Chandelier Exit (Long, 3 ATRs ) 70.4866
Chandelier Exit (Short, 3 ATRs ) 71.7034
Upper Bollinger Band 77.2285
Lower Bollinger Band 64.5855
Percent B (%b) 0.22
BandWidth 17.830398
MACD Line -2.6931
MACD Signal Line -2.3458
MACD Histogram -0.3473
Fundamentals Value
Market Cap 8.38 Billion
Num Shares 124 Million
EPS 0.21
Price-to-Earnings (P/E) Ratio 320.95
Price-to-Sales 13.91
Price-to-Book 31.29
PEG Ratio -7.79
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 70.22
Resistance 3 (R3) 70.39 69.62 69.75
Resistance 2 (R2) 69.62 68.90 69.54 69.60
Resistance 1 (R1) 68.51 68.46 69.07 68.34 69.44
Pivot Point 67.74 67.74 68.02 67.65 67.74
Support 1 (S1) 66.63 67.02 67.18 66.46 65.36
Support 2 (S2) 65.86 66.58 65.77 65.20
Support 3 (S3) 64.75 65.86 65.05
Support 4 (S4) 64.58